ANTIBODY SPECIFICALLY BINDING TO HUMAN CTLA4, AND DRUG AND KIT COMPRISING SAME

Disclosed in the present invention is an antibody specifically binding to human CTLA4, comprising three complementary determining regions. The three complementary determining regions are respectively: CDR1 having an amino acid sequence as shown in SEQ ID NO: 1, CDR2 having an amino acid sequence as shown in SEQ ID NO: 2, and CDR3 having an amino acid sequence as shown in SEQ ID NO: 3. Further disclosed in the present invention are a drug and a kit comprising the antibody. The antibody of the present invention shows the following characteristics but is not limited to the following properties: (1) high affinity and specificity to the human CTLA4 are achieved; (2) the interaction between CTLA4 and CD86 or CD80 can be blocked; (3) CTLA4 overexpression cells can be specifically bound; (4) the activation of PBMC and/or T cells is enhanced; and (5) the tumor growth is inhibited. La présente invention concerne un anticorps se liant de manière spécifique au CTLA4 humain, comprenant trois régions déterminant la complém